We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Hologic (HOLX - Free Report) closed at $75.89, marking a +0.15% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.61%. Meanwhile, the Dow lost 0.42%, and the Nasdaq, a tech-heavy index, added 0.17%.
Prior to today's trading, shares of the medical device maker had gained 1.57% over the past month. This has lagged the Medical sector's gain of 5.48% and outpaced the S&P 500's gain of 0.89% in that time.
Investors will be hoping for strength from Hologic as it approaches its next earnings release. The company is expected to report EPS of $0.87, down 59.91% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $962.24 million, down 34.59% from the prior-year quarter.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $3.46 per share and revenue of $3.81 billion. These results would represent year-over-year changes of -42.52% and -21.56%, respectively.
Investors should also note any recent changes to analyst estimates for Hologic. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Hologic is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Hologic's current valuation metrics, including its Forward P/E ratio of 21.88. Its industry sports an average Forward P/E of 29.41, so we one might conclude that Hologic is trading at a discount comparatively.
We can also see that HOLX currently has a PEG ratio of 1.44. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. HOLX's industry had an average PEG ratio of 2.35 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 90, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HOLX in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Gains As Market Dips: What You Should Know
In the latest trading session, Hologic (HOLX - Free Report) closed at $75.89, marking a +0.15% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.61%. Meanwhile, the Dow lost 0.42%, and the Nasdaq, a tech-heavy index, added 0.17%.
Prior to today's trading, shares of the medical device maker had gained 1.57% over the past month. This has lagged the Medical sector's gain of 5.48% and outpaced the S&P 500's gain of 0.89% in that time.
Investors will be hoping for strength from Hologic as it approaches its next earnings release. The company is expected to report EPS of $0.87, down 59.91% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $962.24 million, down 34.59% from the prior-year quarter.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $3.46 per share and revenue of $3.81 billion. These results would represent year-over-year changes of -42.52% and -21.56%, respectively.
Investors should also note any recent changes to analyst estimates for Hologic. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Hologic is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Hologic's current valuation metrics, including its Forward P/E ratio of 21.88. Its industry sports an average Forward P/E of 29.41, so we one might conclude that Hologic is trading at a discount comparatively.
We can also see that HOLX currently has a PEG ratio of 1.44. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. HOLX's industry had an average PEG ratio of 2.35 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 90, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HOLX in the coming trading sessions, be sure to utilize Zacks.com.